San Jose, CA (PRWEB) October 28, 2008
World Health Organization forecasts global diabetic population to increase by 2025 to reach a record 380 million. Globally, an estimated 246 million people are affected by diabetes mellitus, of which less than half have been identified. Of those identified, approximately 10%-20% are insulin dependent. The seriousness of affliction and the need for effective therapy to manage diabetes has led to the emergence of a significant market for monitoring the treatment efficiency of the disease. Other factors such as greater glucose control, product innovations that help improve compliance or convenience comprise other growth drivers in this market.
Diabetes patients (type I) who regularly monitor their HbA1c (hemoglobin A1C) levels attain tight glucose control, thus considerably reducing their vulnerability to a cardiovascular disease. High blood sugar level for a longer period of time could result to increase in risk of heart disease or stroke. An HBA1C level more that 4.6 indicate the person is at increased risk for heart attack. The ADA (American Diabetes Association), recommends an HbA1c test every 3 to 6 months for monitoring the levels of blood sugar in insulin-administered patients, patients with high blood glucose levels and patients with a change of therapy.
World Hemoglobin (Hb) A1c monitoring market is projected to expand to US$272 million by 2012, as stated by Global Industry Analysts, Inc. The report analyzes the market by two segments: HbA1c Laboratory Testing and HbA1c Point of Care and Self-Monitoring. HbA1c laboratory testing products account for more than two-thirds of the total HbA1c monitoring market, while HbA1c point of care testing & self-monitoring products is forecast to emerge as the faster growing segment. In terms of geographic markets, United States and Europe together account for over 70% of the world market.
Key competitive factors in the market include price, accuracy, test consistency, and effectiveness. Leading players in the global hemoglobin A1c monitoring market include Abbott Laboratories, Axis Shield, Bayer Healthcare, Beckman Coulter, Bio Rad Laboratories, Biosafe Laboratories, Diabetes Technologies, Flexsite Diagnostics, Primus, Roche Diagnostics, Tosoh Bioscience.
The report titled "Hemoglobin A1c Monitoring: A Global Strategic Business Report" published by Global Industry Analysts, Inc., analyzes various market trends and issues shaping the industry. A comprehensive insight is provided on HbA1c laboratory testing and product development initiatives, and diabetes prevalence and incidence rates. The report also offers a review of the recent strategic corporate activity, technological breakthroughs, product developments/introductions, and research and development activities of major global and regional market participants.
For more details about this research report, please visit http://www.strategyr.com/Hemoglobin_A1c_Monitoring_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of over 60,000 smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site http://www.StrategyR.com/